7.6 ± 4.8 eAGT (ng/day) 517.5 ± 677.7 eMCP-1 (ng/day) 279.9 ± 318.7 eMDA (μM/day) 2.5 ± 2.6 eAdiponectin (μg/day) 85.0 ± 120.0 ePodocalyxin (ng/day) 10.1 ± 9.7 Protein intake through eUUN (g/kg/day) ‡ 0.92 ± 0.48 Data are presented as mean ± standard deviation, percent only or percent (range). Group 1, patients with decreased body weight ≥ 1.5% during 16 weeks; group 2, patients with decreased body weight of 1.5-0.1% during 16 weeks; group 3, patients with increased body weight ≥ 0.0% during 16 weeks. AGT, angiotensinogen; AMI, acute myocardial infarction; anti-HTNs, antihypertensive medications; BB, beta-blocker; CCB, calcium channel blocker; CVA, cerebrovascular accident; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; MCP-1, monocyte chemoattractant protein-1; MDA, malondialdehyde; SBP, systolic blood pressure; Ualb, urine albumin; Ucr, urine creatinine concentration; Una, urine sodium; UUN, urine urea nitrogen. P values for continuous variables were estimated by Kruskal-Wallis test, and P values for categorical variables were calculated by Pearson's chi-square test. *Other anti-HTNs, such as α-adrenergic system blockers and vasodilators. † Estimated 24-hr urine parameters were obtained using estimated daily creatinine excretion from the Tanaka equation. ‡ Protein intake was calculated as follows: "24-hr UUN (g/day) + {body weight [18] × 0.031 (g nitrogen/kg/day)} × 6.25 (g protein/day)" and normalized by body weight (g protein/kg body weight/day). *A ratio of estimated urine albumin excretion at the 16-week time point compared to the 0-week time point. P values were estimated by multiple logistic regression analysis adjusted with the related factors to achieve a decrease in podocalyxin, such as history of cerebrovascular accident, diastolic blood pressure, uric acid, total CO 2 , total cholesterol, and albuminuria at baseline, percent changes in white blood cells, hemoglobin, serum K, and albuminiuria over 16 weeks, and group of change in body weight.
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